Physician profile
Mark T Cutright
NPI 1649266057
$5,973.96
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,352 · 2020: $118 · 2021: $1,266 · 2022: $1,239.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gentleman Orthopedic Solutions | $3,960.24 | 2019-2022 | |
| Arthrex, INC. | $1,608.50 | 2019 | |
| Zimmer Biomet Holdings, INC. | $65.47 | 2020-2021 | |
| Avanos Medical | $34.72 | 2019 | |
| Stryker Corporation | $33.07 | 2019 | |
| Smith+Nephew, INC. | $28.58 | 2019 | |
| Pfizer INC. | $27.83 | 2019 | |
| Radius Health, INC. | $26.55 | 2019 | |
| Depuy Synthes Sales INC. | $26.20 | 2020 | |
| Melinta Therapeutics, LLC | $24.89 | 2019 | |
| Endo Pharmaceuticals INC. | $24.71 | 2020 | |
| Conformis, INC. | $21.74 | 2020 | |
| Heraeus Medical, LLC. | $21.66 | 2021-2022 | |
| Heron Therapeutics, INC. | $21.22 | 2021-2022 | |
| Horizon Therapeutics Plc | $15.01 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $14.74 | 2022 | |
| Djo, LLC | $11.61 | 2021 | |
| Orthofix Medical, INC. | $7.22 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cutright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.